Last reviewed · How we verify
A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares
Details
| Lead sponsor | LEO Pharma |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 782 |
| Start date | 2008-02 |
| Completion | 2009-07 |
Conditions
- Psoriasis Vulgaris
Interventions
- Calcipotriol plus hydrocortisone ointment vehicle
- Tacalcitol Ointment
- Calcipotriol plus hydrocortisone ointment
Primary outcomes
- Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8 — Week 8
Countries
Canada, France, United Kingdom